An observational study in Leukemia, sponsored by Assiut University. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Assiut University · Observational
Glycemic control in leukemia patients
Hematological malignancies, particularly leukemia, exhibit complex systemic interactions involving tumor-induced inflammation and metabolic dysregulation. Red Cell Distribution Width (RDW) reflects anisocytosis and is an established biomarker of systemic inflammation, impaired erythropoiesis, and oxidative stress. Elevated pretreatment RDW strongly correlates with adverse survival outcomes across various blood cancers. Concurrently, glycemic metrics such as Glycated Hemoglobin (HbA1c) and Hemoglobin Glycation Index (HGI)-which measures the discrepancy between measured HbA1c and glucose-predicted HbA1c-quantify metabolic dysfunction. A high HGI indicates an altered glycemic environment supporting tumor growth and aggressive disease behavior.
However, raw HbA1c values in leukemia patients are frequently confounded by frequent blood transfusions, disease-related anemia, chemotherapy, and altered erythrocyte lifespan. Evaluating HGI circumvents these confounding artifacts, providing a reliable measure of true metabolic dysregulation. Combining RDW with HGI captures the dual pathophysiological drivers of chronic inflammation and metabolic subversion. This prospective study aims to evaluate the combined prognostic significance of baseline RDW and HGI in predicting survival, disease progression, and overall mortality risk in leukemia patients, establishing an accessible personalized risk stratification model.
2,381 studies on the registry are indexed under Leukemia; 253 are open to participants now.
This study's planned enrollment of 54 is below the median of 142 across 332 observational studies indexed under Leukemia.
Browse Leukemia studies →Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Newly diagnosed adult patients (aged 18 years or older) with histologically/cytologically confirmed leukemia (including Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, or Chronic Lymphocytic Leukemia) presenting to the Clinical Hematology \& Medical Oncology Unit at Assiut University Hospital prior to starting baseline induction chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Provision of written .
Exclusion Criteria:
Active severe co-existing acute infection or sepsis independent of leukemia diagnosis.
Known pre-existing active secondary . Pregnancy or lactation. History of severe hemoglobinopathies (e.g., sickle cell anemia, thalassemia major) that significantly alter erythrocyte lifespan independent of disease.
Incomplete clinical data or loss to follow-up.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Overall Survival (OS)
Time from initial diagnostic blood sampling/enrollment to death from any cause or date of last follow-up
Time frame: Up to 24 months
No study locations are listed for this record.
Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.
Of 96 non-industry observational studies under Leukemia, half reached primary completion within 119 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 269. This study's planned 24 months is below that.
Counting every sponsor, half of 110 studies reached it within 119 months; a quarter within 40 and three quarters within 269.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.